Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®

This study has been completed.

First Received on June 24, 2009. Last Updated on December 20, 2011 History of Changes

Sponsor:	Bayer
Information provided by:	Bayer
ClinicalTrials.gov Identifier:	NCT00927537

Purpose

The efficacy and tolerability of an antihypertensive treatment with Telmisartan is followed over 3-4 months

Condition	Intervention
Hypertension	Drug: Telmisartan (Kinzal/Pritor, BAY68-9291) Drug: Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide

Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	Data Collection on Hypertension and Its Treatment With Kinzal®/ Kinzalplus®

Resource links provided by NLM:

MedlinePlus related topics: High Blood Pressure

Drug Information available for: Hydrochlorothiazide Telmisartan

U.S. FDA Resources

Further study details as provided by Bayer:

Primary Outcome Measures:

Blood pressure [ Time Frame: After 1-2 weeks, 1month, 3-4 months ] [ Designated as safety issue: No ]

Enrollment:	2079
Study Start Date:	April 2008
Study Completion Date:	October 2011

Groups/Cohorts	Assigned Interventions
Group 1	Drug: Telmisartan (Kinzal/Pritor, BAY68-9291) Patients under daily life treatment receiving Kinzal according to local drug information.
Group 2	Drug: Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide Patients under daily life treatment receiving Kinzalplus according to local drug information.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Community

Criteria

Inclusion Criteria:

Hypertensive patients seen by the physician requiring antihypertensive treatment

Exclusion Criteria:

According to the local drug information

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00927537

Locations

Switzerland

Many Locations, Switzerland

Sponsors and Collaborators

Bayer

Investigators

Study Director:

Bayer Study Director

Bayer

More Information

Additional Information:

Click here and search for drug information provided by the FDA. This link exits the ClinicalTrials.gov site

Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product. This link exits the ClinicalTrials.gov site

No publications provided

Responsible Party:	Medical Director, Bayer HealthCare AG
ClinicalTrials.gov Identifier:	NCT00927537 History of Changes
Other Study ID Numbers:	13599, KL0810CH
Study First Received:	June 24, 2009
Last Updated:	December 20, 2011
Health Authority:	Switzerland: None

Keywords provided by Bayer:

Hypertension

Additional relevant MeSH terms:

Hypertension
Vascular Diseases
Cardiovascular Diseases
Hydrochlorothiazide
Telmisartan
Diuretics
Natriuretic Agents
Physiological Effects of Drugs
Pharmacologic Actions
Sodium Chloride Symporter Inhibitors

Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents
Cardiovascular Agents
Therapeutic Uses
Angiotensin II Type 1 Receptor Blockers
Angiotensin Receptor Antagonists
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors

ClinicalTrials.gov processed this record on February 09, 2012